Cargando…

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer

The FDA-approved anti-androgen Enzalutamide (Enz) has been used successfully as the last line therapy to extend castration-resistant prostate cancer (CRPC) patients’ survival by an extra 4.8 months. However, CRPC patients eventually develop Enz-resistance that may involve the induction of the androg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chou, Fu-Ju, Lin, ChangYi, Tian, Hao, Lin, WanYing, You, Bosen, Lu, Jieyang, Sahasrabudhe, Deepak, Huang, Chi-Ping, Yang, Vanessa, Yeh, Shuyuan, Niu, Yuanjie, Chang, Chawnshang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606511/ https://www.ncbi.nlm.nih.gov/pubmed/33139720 http://dx.doi.org/10.1038/s41419-020-02970-4

Ejemplares similares

Preclinical studies show using enzalutamide is less effective in docetaxel-pretreated than in docetaxel-naïve prostate cancer cells
por: Lin, Changyi, et al.
Publicado: (2020)

Preclinical Study Using ABT263 to Increase Enzalutamide Sensitivity to Suppress Prostate Cancer Progression Via Targeting BCL2/ROS/USP26 Axis Through Altering ARv7 Protein Degradation
por: Xu, Hua, et al.
Publicado: (2020)

The miR-361-3p increases enzalutamide (Enz) sensitivity via targeting the ARv7 and MKNK2 to better suppress the Enz-resistant prostate cancer
por: Liu, Bianjiang, et al.
Publicado: (2020)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

Suppressing BCL-XL increased the high dose androgens therapeutic effect to better induce the Enzalutamide-resistant prostate cancer autophagic cell death
por: Xiang, Zhendong, et al.
Publicado: (2021)

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
por: Li, Yan, et al.
Publicado: (2022)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
por: Cochrane, Dawn R, et al.
Publicado: (2014)

TNF signaling mediates an enzalutamide-induced metastatic phenotype of prostate cancer and microenvironment cell co-cultures
por: Sha, Kai, et al.
Publicado: (2015)

Targeting the radiation-induced ARv7-mediated circNHS/miR-512-5p/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity
por: Chen, Dong, et al.
Publicado: (2022)

Infiltrating neutrophils increase bladder cancer cell invasion via modulation of androgen receptor (AR)/MMP13 signals
por: Lin, ChangYi, et al.
Publicado: (2015)

Preclinical study using circular RNA 17 and micro RNA 181c-5p to suppress the enzalutamide-resistant prostate cancer progression
por: Wu, Gang, et al.
Publicado: (2019)

High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling
por: Chen, Lei, et al.
Publicado: (2022)

LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling
por: Luo, Jie, et al.
Publicado: (2019)

Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals
por: Deng, Gang, et al.
Publicado: (2021)

Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression
por: Zhang, Meng, et al.
Publicado: (2021)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

Clinical Pharmacokinetic Studies of Enzalutamide
por: Gibbons, Jacqueline A., et al.
Publicado: (2015)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Changing the Timing of Enzalutamide Intake from Morning to before Sleep at Night Overcame Enzalutamide-Induced Dysgeusia
por: Kawahara, Takashi, et al.
Publicado: (2019)

The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
por: Zheng, Zeyuan, et al.
Publicado: (2022)

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
por: Ware, Kathryn E., et al.
Publicado: (2016)

Pharmacokinetic Drug Interaction Studies with Enzalutamide
por: Gibbons, Jacqueline A., et al.
Publicado: (2015)

Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients
por: Luo, Yong, et al.
Publicado: (2021)

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide
por: Del Re, M., et al.
Publicado: (2021)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
por: Alumkal, Joshi J., et al.
Publicado: (2020)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
por: Hong, Zhe, et al.
Publicado: (2021)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Observational study on time on treatment with abiraterone and enzalutamide
por: Fallara, Giuseppe, et al.
Publicado: (2020)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

Analysis of novel enzalutamide-resistant cells: upregulation of testis-specific Y-encoded protein gene promotes the expression of androgen receptor splicing variant 7
por: Seki, Masanao, et al.
Publicado: (2020)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
por: Smith, Rebecca, et al.
Publicado: (2020)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

Collateral resistance to taxanes in enzalutamide‐resistant prostate cancer through aberrant androgen receptor and its variants
por: Shiota, Masaki, et al.
Publicado: (2018)

Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide
por: Hoefer, Julia, et al.
Publicado: (2016)

Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment
por: Xu, Pengfei, et al.
Publicado: (2023)

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
por: Graff, Julie N, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_05n7gecobkas6udfr1grv0qvuk